Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348

VIFOR PHARMA

(VIFN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
124.5(c) 126.15(c) 122.55(c) 121.4(c) 122.5 Last
189 068 265 521 295 303 258 024 29 672 Volume
-0.80% +1.33% -2.85% -0.94% +0.91% Change
More quotes
Financials
Sales 2020 1 884 M 2 062 M 2 062 M
Net income 2020 291 M 318 M 318 M
Net cash position 2020 397 M 435 M 435 M
P/E ratio 2020 26,4x
Yield 2020 1,71%
Sales 2021 2 023 M 2 215 M 2 215 M
Net income 2021 261 M 286 M 286 M
Net cash position 2021 686 M 751 M 751 M
P/E ratio 2021 30,9x
Yield 2021 1,69%
Capitalization 7 878 M 8 642 M 8 622 M
EV / Sales 2020 3,97x
EV / Sales 2021 3,55x
Nbr of Employees 2 733
Free-Float 71,8%
More Financials
Company
Vifor Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency and nephrological and cardiovascular disorders. Vitor Pharma also markets a diversified portfolio of prescription drugs and OTC products. At the end of 2017, Vifor Pharma has a portfolio of 4 products in clinical development of which 3 in phase III, 1 in phase II and 1... 
More about the company
Notations Surperformance© of Vifor Pharma
Trading Rating : Investor Rating :
More Ratings
All news about VIFOR PHARMA
11/19VIFOR PHARMA : VFMCRP and Fresenius Kabi expand collaboration in nephrology in C..
BU
11/16VIFOR PHARMA : Full results from affirm-ahf study show ferinject significantly r..
AQ
11/13VIFOR PHARMA : Full Results From AFFIRM-AHF Study Show Ferinject® Significantly ..
BU
11/09Switzerland's Vifor strikes kidney drug deal with Angion
RE
11/09VIFOR PHARMA : and Angion Sign License Agreement for ANG-3777 in Nephrology Indi..
BU
11/04ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to re..
AQ
11/03VIFOR PHARMA : VFMCRP and ChemoCentryx announce European Medicines Agency has ac..
BU
10/21Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva t..
AQ
10/20VIFOR PHARMA : and Cara Therapeutics sign US license agreement for i.v. Korsuva&..
BU
09/25VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
AQ
09/24VIFOR PHARMA : announces outcome of AFFIRM-AHF topline data
BU
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, Moderna…
09/18VIFOR PHARMA GROUP : Announces Successful Sale of OM Pharma
BU
09/01VIFOR PHARMA : Appoints Gregory Oakes as President North America and Member of t..
BU
08/06VIFOR PHARMA GROUP : Reports Continued Growth in H1 2020
BU
More news
News in other languages on VIFOR PHARMA
11/19Vifor-Joint-Venture und Fresenius Kabi erweitern Zusammenarbeit in China
11/19VFMCRP et Fresenius Kabi étendent leur collaboration en Chine
11/17Principales informations avant-Bourse
11/17Morning Briefing - Markt Schweiz
11/16VIFOR : l'action en hausse après de nouvelles données sur le Ferinject
More news
Chart VIFOR PHARMA
Duration : Period :
Vifor Pharma Technical Analysis Chart | VIFN | CH0364749348 | MarketScreener
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 146,58 CHF
Last Close Price 121,40 CHF
Spread / Highest target 56,5%
Spread / Average Target 20,7%
Spread / Lowest Target -1,15%
EPS Revisions
Managers
NameTitle
Stefan Schulze President, Chief Executive & Operating Officer
Jacques Theurillat Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Etienne Jornod Honorary Chairman
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA-31.28%8 642
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273